На этой странице перечислены больницы направления «Урология» (включая Peyronie's Disease Treatment) в Хайдарабад, Индия, включая KIMS Hospitals, Secunderabad, Yashoda Hospitals, Secunderabad, Apollo Hospital DRDO, Apollo Hospitals, Jubilee Hills.
Спросите нас о «Peyronie's Disease Treatment» в Хайдарабад, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 4 аккредитованных больниц (Урология) в Хайдарабад, Индия
Рекомендуем🇮🇳 KIMS Hospitals, Secunderabad
Больница занимает 1-е место в этом списке по указанному рейтингу (4.8/5, 743 отзывов).
🇮🇳 Yashoda Hospitals, Secunderabad
Больница занимает 2-е место в этом списке по указанному рейтингу (4.7/5, 518 отзывов).
🇮🇳 Apollo Hospital DRDO
Больница занимает 3-е место в этом списке по указанному рейтингу (4.5/5, 82 отзывов).
🇮🇳 Apollo Hospitals, Jubilee Hills
Больница занимает 4-е место в этом списке по указанному рейтингу (4.1/5, 44 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Урология» указано среди её специализаций и она находится в Хайдарабад, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «peyronie's disease treatment» в Хайдарабад, Индия?
Выбор подходящей больницы для «peyronie's disease treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Урология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Peyronie's Disease Treatment»
Peyronie's Disease Treatment encompasses a spectrum of evidence-based interventions—from pharmacological collagenase injections (Xiaflex/CCH) and intralesional verapamil to surgical plaque excision with grafting and penile prosthesis implantation—achieving clinically meaningful curvature correction and functional restoration in 70–90% of appropriately selected patients. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed centres in Dubai and Abu Dhabi, where fellowship-trained andrologists and urologists deliver these complex procedures at a fraction of Western costs. Patients benefit from zero waiting lists, end-to-end concierge coordination, and internationally benchmarked outcomes that make India and the UAE the leading destinations for affordable, high-quality Peyronie's Disease care. Hospital Stay: 1–3 days (non-surgical/injection therapy: outpatient; surgical correction: 1–3 days inpatient) • Total Stay in Country (Fit-to-Fly): 1–3 weeks (injection series: 1 week post-final cycle; surgical cases: 2–3 weeks post-operatively, surgeon-cleared) • Success Rate: 70–90% (curvature correction ≥20°; prosthetic implantation satisfaction >90%)
Clinical Overview
Peyronie's Disease (PD) is a fibrotic disorder of the tunica albuginea—the dense fibro-elastic sheath encasing the erectile bodies—characterised by the formation of inelastic collagen plaques (predominantly Type III collagen replacing Type I) that disrupt penile biomechanics. The plaques create a tethering effect during erection, producing penile curvature (typically dorsal, ranging 30°–90°+), hourglass deformity, hinge defect, or shortening, and in moderate-to-severe cases cause penetration-impairing deformity, coital pain, and erectile dysfunction (ED) in up to 79% of affected men. The condition has an estimated prevalence of 3–9% in adult males, though real-world figures are likely higher due to under-reporting, and it is increasingly recognised in men aged 30–70, frequently following blunt or repetitive micro-trauma during intercourse. Physiologically, the fibrotic cascade is driven by TGF-β1-mediated myofibroblast activation and reactive oxygen species, leading to progressive plaque calcification over a 12–18 month 'active phase', after which the disease typically stabilises into the 'chronic/stable phase'. The active phase is characterised by painful erections and changing curvature; the chronic phase features a fixed deformity and resolution of pain. This biological staging directly determines treatment eligibility: intralesional and mechanical therapies are most effective during active or early chronic phases, while surgical reconstruction is reserved for men in the stable chronic phase with a deformity that precludes satisfactory intercourse. The standard of care, as defined by the American Urological Association (AUA) and European Association of Urology (EAU) guidelines, stratifies treatment by disease phase, deformity severity (measured by dynamic duplex ultrasound or a validated penile photograph with a goniometer), erectile function (assessed by IIEF-5 scoring), and patient goals. Collagenase Clostridium histolyticum (CCH/Xiaflex) remains the only FDA-approved intralesional pharmacotherapy, recommended for men with stable disease, palpable plaque, and curvature ≥30°. Surgical options—Nesbit/modified plication for mild-to-moderate curvature with adequate penile length, and plaque incision/excision with grafting (pericardium, SIS, or TachoSil) for severe or complex deformity—are the definitive correction standards. Men with concurrent refractory ED are best served by inflatable penile prosthesis (IPP) implantation with intraoperative modelling.
Who is a Candidate?
• IDEAL SURGICAL CANDIDATES (Plaque Incision/Excision with Grafting or Plication): - Stable Peyronie's Disease: curvature unchanged for ≥3 months (AUA definition of stability) - Curvature ≥30° causing penetration difficulty or complete inability to have intercourse - Adequate baseline erectile function (IIEF-5 ≥17) or ED responsive to PDE5 inhibitors (for plication/grafting procedures) - Penile length sufficient to tolerate plication (typically >11 cm stretched penile length; shorter cases directed toward grafting) - Hourglass, hinge, or multiplanar deformity not correctable by plication alone • IDEAL CANDIDATES FOR COLLAGENASE CCH (XIAFLEX) INJECTION SERIES: - Active or early stable phase PD with curvature 30°–90° - Palpable, non-calcified plaque on physical examination confirmed by high-frequency (7.5–15 MHz) penile ultrasound - Absence of septal scar or calcium deposits (calcified plaques respond poorly to enzymatic therapy) - Patient willing to perform penile modelling/stretching exercises and use vacuum erection device (VED) between cycles • CANDIDATES FOR INFLATABLE PENILE PROSTHESIS (IPP) WITH MODELLING: - Peyronie's Disease with concurrent severe or refractory ED non-responsive to pharmacotherapy - Men who prioritise both curvature correction and reliable erection restoration in a single procedure - Stable disease phase mandatory before prosthetic implantation • REQUIRED DIAGNOSTIC WORK-UP: - Penile Dynamic Duplex Ultrasound (PDDU): peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistive index to characterise plaque location, calcification, and vascular status (venous leak assessment) - Standardised Erect Penile Photography: goniometric curvature measurement in each plane; PDDU-assisted pharmacological erection (intracavernosal alprostadil 10–20 mcg) for objective deformity mapping - IIEF-5 (International Index of Erectile Function) questionnaire: baseline erectile function scoring - PDQ (Peyronie's Disease Questionnaire): validated bother score for symptom severity and psychosocial impact - Serum testosterone, fasting glucose, HbA1c, lipid panel: metabolic co-morbidity assessment - Serum PSA (if age >45): pre-surgical baseline - Full Blood Count, Coagulation Profile (PT/INR/aPTT), Renal and Liver Function Tests: pre-operative fitness • CONTRAINDICATIONS: - Active phase PD with evolving curvature: surgery is contraindicated until disease is stable - Calcified plaque: relative contraindication to CCH injection; ultrasound or plain X-ray must confirm absence of calcification before enzymatic therapy - Active penile or systemic infection: absolute contraindication to any invasive procedure - Severe coagulopathy or anticoagulation not bridgeable perioperatively - Unrealistic patient expectations regarding penile length restoration (counselling mandatory pre-operatively) - Concurrent active malignancy under treatment
Treatment Options & Approaches
PHARMACOLOGICAL / MINIMALLY INVASIVE THERAPIES 1. Intralesional Collagenase Clostridium histolyticum (CCH / Xiaflex) The only FDA/EMA-approved pharmacotherapy. A standard treatment cycle consists of 2 injections administered 24–72 hours apart into the plaque, followed by penile modelling under physician guidance, repeated up to 4 cycles (8 injections total) at 6-week intervals. CCH selectively cleaves Type I and III collagen fibres within the plaque. The IMPRESS I & II pivotal trials demonstrated a mean curvature improvement of ~34% (vs. ~18% placebo) and significant PDQ bother score reduction. GAF partner centres use high-resolution ultrasound guidance for injection precision, reducing the risk of corporal injury. Penile traction therapy (PTT) with a validated device (FastSize, RestoreX) is initiated between injection cycles to augment length recovery and modelling effect. 2. Intralesional Verapamil (ILV) Calcium-channel blocker injected directly into the plaque (10 mg/10 mL in saline; biweekly for 6 months). Mechanistically inhibits fibroblast proliferation and stimulates collagenase activity, reducing plaque volume. Used primarily in active-phase disease or as an adjunct when CCH is unavailable or contraindicated. Response rates for curvature improvement are modest (~25–30%) but the safety profile is favourable. 3. Intralesional Interferon-α2b Biological agent that downregulates TGF-β1 and reduces fibroblast proliferation. Administered biweekly for 12 weeks; supported by RCT data showing curvature improvement and pain reduction. Considered when CCH is not accessible. 4. Extracorporeal Shockwave Therapy (ESWT) Low-intensity focused shockwaves applied transcutaneously to the plaque (typically 2,000–3,000 pulses at 0.09–0.25 mJ/mm², 3 sessions/week for 3–6 weeks). Primarily effective for pain relief in the active phase; evidence for curvature correction is limited and the AUA does not recommend it as a curvature-correcting monotherapy but it is widely used for pain management. 5. Penile Traction Therapy (PTT) & Vacuum Erection Device (VED) Standalone or adjunctive mechanical therapies applying controlled tensile force to remodel scar tissue. Validated devices (RestoreX) used ≥30 minutes/day over 3–6 months show curvature reductions of 15–25° and length gains of 0.5–1.5 cm in clinical studies. Used perioperatively to protect penile length. SURGICAL THERAPIES (Stable/Chronic Phase) 6. Penile Plication (Nesbit Procedure & Modified Variants: 16-dot, Yachia) The gold standard for men with mild-to-moderate curvature (≤60°), no significant hourglass/hinge deformity, and adequate penile length. The convex (opposite) side of the tunica albuginea is plicated using permanent (Prolene 2-0) or absorbable sutures to counteract the curvature produced by the inelastic plaque. The procedure avoids plaque manipulation, carries minimal erectile function risk, and has a high patient satisfaction rate (~80–85%). It does result in a degree of penile shortening (typically 0.5–2 cm), which must be counselled pre-operatively using the Kelâmi nomogram. 7. Plaque Incision / Excision with Grafting (Lue Technique, H-incision) Indicated for severe curvature (>60°), significant shortening, or complex multiplanar or hourglass/hinge deformity where plication would sacrifice excessive length. The plaque is incised (H-shape, fish-mouth) or partially excised, creating a defect that is covered with a graft. Graft materials in current use include: - Pericardial allograft (bovine or equine): widely used, excellent handling properties - Small Intestinal Submucosa (SIS/Surgisis): acellular biocompatible matrix - Tunica vaginalis autograft: patient's own tissue, no rejection risk - TachoSil (fibrin sealant patch): emerging evidence in small series Grafting carries a higher risk of de novo ED (5–25% depending on baseline vascular status) due to dissection near neurovascular bundles; intraoperative pharmacological erection testing with duplex assessment is performed to verify deformity correction and graft integrity. Penile Doppler imaging pre-operatively stratifies vascular risk. 8. Inflatable Penile Prosthesis (IPP) Implantation with Manual Modelling The procedure of choice for men with PD and concurrent severe/refractory ED. A 3-piece IPP (AMS 700 CX, Coloplast Titan, or equivalent) is implanted via a subcoronal or infrapubic approach. Following cylinder placement, the device is fully inflated and the penis is manually modelled (Mulcahy technique) to fracture or stretch the plaque and achieve straightening. Residual curvature >30° post-modelling can be addressed by adjunctive incision/grafting over the prosthesis or plication. Curvature correction rates exceed 85%; patient satisfaction rates for IPP in this indication exceed 90% in long-term series. GAF partner centres perform this procedure laparoscopically-assisted in select cases for improved visualisation.
Восстановление
PRE-OPERATIVE / PRE-TREATMENT PHASE (Days 1–7 after arrival) Day 1–2: Arrival & Consultation • Airport transfer by GAF Healthcare coordinator; hotel or hospital guest house check-in • Comprehensive andrology/urology consultation with review of all prior imaging and records sent in advance • Baseline penile dynamic duplex ultrasound (PDDU) with pharmacological erection (intracavernosal alprostadil) • Standardised erect penile photography with goniometric curvature measurement • IIEF-5 and PDQ questionnaire administration • Blood work: CBC, coagulation, metabolic panel, testosterone, HbA1c, PSA • Anaesthesia fitness assessment (ECG, chest X-ray if indicated) Day 3–4: Multidisciplinary Review & Treatment Planning • Andrologist, anaesthetist, and nurse coordinator team review all diagnostics • Shared decision-making consultation: patient and family briefed on all options (injection series vs. surgery), risks, realistic outcomes, and penile length impact • Consent obtained; surgical scheduling confirmed or injection programme started • Cardiological or endocrinological clearance arranged same-day if metabolic co-morbidities identified Day 5–7 (if surgical): Pre-operative Preparation • NPO (nil per os) from midnight before surgery • Bowel prep not required; antiseptic shower • Pre-operative antibiotics (cefazolin 1g IV or allergy-adjusted alternative) administered 30–60 min pre-incision • Thromboprophylaxis: TED stockings + LMWH (enoxaparin) initiated evening before or per anaesthesia protocol INTRA-OPERATIVE PHASE (Day of Surgery: typically Day 5–7) Surgical Duration: • Plication procedures: 60–90 minutes under spinal or general anaesthesia • Plaque excision with grafting: 2–3 hours under general anaesthesia • IPP implantation with modelling: 2–3 hours under spinal or general anaesthesia Key Intraoperative Steps (Grafting/Plication example): 1. Subcoronal circumferential incision with degloving of penile skin to expose tunica albuginea 2. Neurovascular bundle identification and protection (Buck's fascia dissection) 3. Artificial pharmacological erection induction (intracavernosal saline/alprostadil) to map deformity precisely 4. Plaque incision (H-configuration) or plication suture placement at maximum curvature point 5. Graft inset and fixation (for grafting cases); repeat artificial erection to confirm straightening 6. Watertight closure; skin re-approximation; compressive dressing and urinary catheter placement IMMEDIATE POST-OPERATIVE PHASE (Day 1–3 post-surgery in hospital) • Urinary catheter remains in situ 24–48 hours • IV analgesia (paracetamol + NSAID ± opioid PRN); transition to oral analgesia Day 1 • Penile dressing change Day 1; wound inspection • Thromboprophylaxis continued until mobile • Discharge criteria: voiding independently, pain controlled on oral medications, no signs of haematoma or infection • For IPP patients: pump cycling education with nurse before discharge EARLY RECOVERY (Weeks 1–3 in-country) Week 1: • Wound care instructions; waterproof dressing; avoid submersion (no baths/pools) • Oral antibiotics (typically ciprofloxacin or trimethoprim/sulfamethoxazole) for 5–7 days • Penile oedema and bruising expected; ice pack intervals • Strict sexual abstinence; no manual stimulation • PDE5 inhibitor initiated at low dose (sildenafil 25–50 mg nightly) from Day 14 post-grafting to promote oxygenated blood flow and protect erectile function (penile rehabilitation protocol) • Follow-up clinic review at Day 7: wound check, early deformity assessment Week 2–3: • Penile traction device (PTT) initiated at Week 3 post-surgery (plication/grafting cases) to mitigate scar contracture and preserve length • IPP patients begin device cycling (inflation/deflation) at 4–6 weeks under instruction • Surgeon-issued fit-to-fly certificate typically issued at 2–3 weeks for surgical cases (confirmed at follow-up visit before departure) • GAF coordinator arranges discharge summary, imaging reports, operative notes, and pathology (if plaque excised) for handover to home country physician MID-TO-LONG-TERM RECOVERY (Weeks 4–24 at home) Week 4–6: Return of spontaneous erections; continued penile rehabilitation with PDE5i and PTT Week 6–8: Sexual activity may resume (surgeon clearance required); gradual return to full activity Week 12: Formal assessment of curvature correction; IIEF-5 and PDQ re-administered Months 6–12: Final functional and cosmetic outcome assessment; residual curvature addressed if >15° and symptomatic (rarely required) FOR INJECTION (CCH) PROGRAMME PATIENTS: • Cycle 1: Injections Day 1 & Day 3; modelling session Day 3; discharge Day 4 • Return for Cycles 2–4 at 6-week intervals (GAF coordinates telemedicine monitoring between visits) • Fit-to-fly: 5–7 days after each injection cycle • Full programme completion: 6 months (4 cycles); final outcome assessment at Month 6
Возможные риски
Peyronie's Disease Treatment, while generally safe in experienced hands, carries a spectrum of procedure-specific risks that patients must understand before proceeding. For intralesional CCH (Xiaflex) injection therapy, the most serious risk is corporal rupture (penile fracture equivalent), reported in <1% of cases in the IMPRESS trials; it requires immediate surgical repair and is mitigated by strict adherence to injection technique and modelling protocols. Bruising, swelling, and injection-site pain are nearly universal after each cycle (>85%) and resolve within 2–4 weeks. Skin break or penile skin tears occur in ~5% and typically heal conservatively. For surgical plication procedures, the primary risk is penile shortening (0.5–2.0 cm), which is predictable and should be quantified pre-operatively using Kelâmi's formula; de novo ED is rare (<5%) as the plaque is not disturbed. For plaque incision/excision with grafting, the most clinically significant risk is de novo or worsened ED, occurring in 5–25% of cases depending on baseline vasculogenic status (PDDU-measured PSV <25 cm/s pre-operatively is a significant risk factor); partial sensory changes or glans hypoaesthesia from neurovascular bundle proximity can occur in 5–15% and are usually transient. Recurrent curvature is reported in 5–10% of cases at 5-year follow-up for all surgical approaches. For inflatable penile prosthesis (IPP) implantation, device infection is the most feared complication (1–3% in antibiotic-coated devices such as AMS 700 InhibiZone or Coloplast Titan OTR), requiring device explantation if it occurs; mechanical failure rates are <5% at 10 years with modern 3-piece devices. Residual curvature post-IPP modelling (>30°) requiring adjunctive intervention occurs in approximately 10–15% of cases. Across all interventions, patients should be counselled that Peyronie's Disease cannot be fully 'cured' in the sense of complete plaque elimination; the realistic goal is functional straightening sufficient for intercourse, with variable length and girth outcomes. Patients with significant psychosexual distress related to PD should receive concurrent psychological support, as depression and relationship impact are documented in >50% of affected men.
Почему GAF Healthcare
GAF Healthcare provides a fully managed, end-to-end medical tourism experience for Peyronie's Disease Treatment in both India and the UAE, encompassing every non-clinical touchpoint from pre-departure to post-treatment repatriation. INDIA LOGISTICS: • e-Medical Visa Assistance: GAF's India visa desk prepares and submits the complete e-Medical Visa application on the patient's behalf, including the mandatory hospital invitation letter from our partner JCI/NABH-accredited institution, ensuring approvals are typically secured within 3–5 business days. Extension applications are managed if the clinical stay is prolonged. • Airport Transfers: Private air-conditioned vehicle transfers between the international airport and hospital/hotel are arranged for the patient and up to 2 accompanying attendants at all hours. • Dedicated Bilingual Coordinator: A personal GAF case coordinator—fluent in English and the patient's native language—accompanies the patient to all clinical appointments, translates between the medical team and patient, and manages all administrative paperwork within the hospital. • Attendant Accommodation: GAF arranges serviced apartments or hospital guest houses within walking distance of partner hospitals (available in Delhi, Mumbai, Chennai, Hyderabad, Bengaluru) at preferential rates, with meal, laundry, and SIM card support included in premium packages. • Telemedicine Follow-Up: Post-departure, patients are enrolled in GAF's structured telemedicine programme—video consultations with the treating andrologist at Day 30, Day 90, and Month 6—ensuring continuity of the penile rehabilitation protocol and early identification of any complications. UAE LOGISTICS: • Visa Entry: Nationals of over 50 countries receive visa-on-arrival or visa-free access to the UAE for up to 30–90 days, covering the full treatment and recovery period for most international patients. GAF's UAE visa desk assists with prior-entry medical visa applications for nationalities requiring advance approval, coordinating with partner hospitals in Dubai Healthcare City (DHA-licensed) and Abu Dhabi (DoH-licensed). • Airport Transfers: Luxury vehicle transfers (SUV or executive sedan) between Dubai International (DXB), Abu Dhabi International (AUH), or Al Maktoum International (DWC) and the patient's hospital or hotel are provided with meet-and-greet service. • Hotel & Recovery Accommodation: GAF partners with medically adjacent hotels in Dubai Healthcare City and near Cleveland Clinic Abu Dhabi and Mediclinic City Hospital, offering in-room nursing check-in services for post-surgical recovery patients. • Interpreter Services: On-call certified medical interpreters in Arabic, Russian, French, Urdu, and other languages are available for all consultations. • Concierge & Lifestyle Support: For extended UAE stays, GAF's concierge team manages leisure recommendations, family activities, halal/dietary-specific meal arrangements, and prayer facility access—ensuring accompanying family members are comfortable throughout the medical journey. ACROSS BOTH DESTINATIONS: • Pre-Travel Medical File Review: All diagnostic records, imaging, and clinical notes are reviewed by a GAF-affiliated specialist prior to travel, providing a second-opinion report and a confirmed treatment plan so the patient arrives with a clear care pathway. • Emergency Medical Liaison: 24/7 WhatsApp and phone access to GAF's medical case management team for any acute clinical concern during the in-country stay. • Discharge Documentation: Comprehensive discharge pack including operative report, histopathology (if applicable), post-operative protocol, medication list, and fit-to-fly certificate provided in English and the patient's preferred language.
Частые вопросы о процедуре «Peyronie's Disease Treatment»
What is the cost of Peyronie's Disease Treatment in India compared to the UAE?
How long do I need to stay in the country before I am fit to fly home after Peyronie's Disease Treatment?
What is the success rate of Peyronie's Disease Treatment, and what outcomes should I realistically expect?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «peyronie's disease treatment» в Хайдарабад, Индия
Найдите лучшие больницы для «peyronie's disease treatment» в Хайдарабад, Индия
На этой странице представлено 4 больниц в Хайдарабад, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Peyronie's Disease Treatment» в Хайдарабад, Индия
Сколько больниц направления «Урология» представлено в Хайдарабад, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Хайдарабад, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Peyronie's Disease Treatment» в Хайдарабад, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.